Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

2100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-10-31

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomised trial for children with acute lymphoblastic leukemia, using the detection of minimal residual disease to define risk groups, aiming to answer the questions:

1. Can treatment be reduced without compromising efficacy in a MRD-defined low risk group?
2. Does further post-remission intensification improve outcome for a MRD-defined high risk group?
3. Measure the Quality of Life impact of the different treatment arms on the children and their families.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

NCT00003437

Leukemia

UNKNOWN PHASE3

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

NCT04726241

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy +5 more

RECRUITING PHASE1/PHASE2

Study of Long-Term Outcomes of Patients With Acute Lymphoblastic Leukemia Who Were Enrolled as Children on Clinical Trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881 Between 1971 and 1998

NCT01298388

Cancer Survivor Leukemia Long-term Effects Secondary to Cancer Therapy in Children

UNKNOWN

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia

NCT00002499

Leukemia

UNKNOWN PHASE2/PHASE3

Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch

NCT03627208

Leukemia, Lymphoblastic, Acute ALL, Childhood

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Randomisations

Patients will be assigned to MRD risk groups based on day 29 and post consolidation MRD results and randomised as follows:

1. MRD Low Risk Group (MRD negative at day 29 and week 11 or positive \<1 x 10-4 at day 28 and negative at week 11) will continue on previously assigned Regimens (A or B) but randomised between two delayed intensifications and one delayed intensification.
2. MRD High Risk Group (MRD positive \> 1 x 10-4 at day 29) randomised between previously assigned Regimen (A or B) and Regimen C.
3. MRD Indeterminate Group (No MRD result or MRD positive \<1 x 10-4 at day 29 and at week 11) will continue on previously assigned Regimen (A or B) and received two delayed intensifications

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Lymphoblastic Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A or B with 2DI

3 or 4 drug induction plus 2 delayed intensifications

Group Type ACTIVE_COMPARATOR

Standard childhood UK ALL protocol

Intervention Type DRUG

No additional treatment to standard protocol.

C plus 2DI

Intensified treatment including Capizzi maintenance

Group Type EXPERIMENTAL

Intensified treatment including Capizzi maintenance

Intervention Type DRUG

Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase

A or B with 1DI

Reduced intensity treatment

Group Type EXPERIMENTAL

Reduced intensification

Intervention Type OTHER

Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Reduced intensification

Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.

Intervention Type OTHER

Standard childhood UK ALL protocol

No additional treatment to standard protocol.

Intervention Type DRUG

Intensified treatment including Capizzi maintenance

Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Removal of second delayed intensification

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Children aged 1 - 18 years with ALL except the following:

1. Standard or Intermediate Risk as defined above.
2. Morphological Complete Remission (BM1 Marrow) at Day 29 of Induction.
3. Availability of MRD results at Day 28 and after consolidation therapy.
4. Informed consent obtained.
5. Induction given as protocol.

Exclusion Criteria

1. Infants less than a year old should be entered onto the Interfant ALL study.
2. Children with B-ALL (Burkitt-like, t(8;14), L3 morphology, SMIg positive). Patients with this disease will be eligible for the current UKCCSG B cell NHL/ALL trial.
3. Children with Philadelphia-positive ALL (t(9;22) or BCR/ABL positive) will start induction therapy on this protocol but transfer to the European Intergroup Protocol as soon as their Philadelphia status is known.

Initially, eligible patients will be stratified into three risk groups based on the following criteria:

1. Standard risk: all children \>1\<10 years with a highest white cell count before starting treatment of \<50x109/l, and who do not have BCR-ABL, hypodiploidy (≥44 chromosomes), or an MLL gene rearrangement.
2. Intermediate risk: all children ≥10 years old, or with a diagnostic WBC ≥50x109/l (or both) and who do not have BCR-ABL, hypodiploidy (≥44 chromosomes), or an MLL gene rearrangement.
3. High Risk: all children, irrespective of initial risk category, who have a slow early response (SER) as defined below - see section 6 - together with those who have BCR-ABL (induction only), hypodiploidy (≥44 chromosomes), or an MLL gene rearrangement. These patients will not be eligible for MRD randomisation.

Patients will then start treatment according to their risk group as follows:

1. Standard risk, (around 60-65% of the total): regimen A - three-drug induction.
2. Intermediate risk, (around 20- 30% of the total): regimen B - four-drug induction.
3. High risk (around 10-12% of the total): These patients will not be eligible for MRD randomisation. They will be allocated regimen C - four drug induction, augmented BFM consolidation, Capizzi interim maintenance, and two further BFM-style intensification periods of extended duration.

1. High Risk as defined above. These patients will receive Regimen C.
2. Day 28 non-remitters. These patients will receive Regimen C if BM2 or go off-protocol if BM3 (see below for definitions of BM2 and BM3).
3. MRD Indeterminate Group (No result or MRD positive \< 1 x 10-4 at day 28 and after consolidation therapy) will continue on previously assigned therapy.
4. Sub-optimal induction therapy. The clinical significance of day 28 MRD is uncertain in patients who have received sub-optimal induction therapy. Please discuss these patients with a co-ordinator.

Minimum Eligible Age

1 Year

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No